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Abstract
Components of bacteria have been shown to induce innate antiviral immunity via Toll-like receptors (TLRs). We have
recently shown that FimH, the adhesin portion of type 1 fimbria, can induce the innate immune system via TLR4. Here we
report that FimH induces potent in vitro and in vivo innate antimicrobial responses. FimH induced an innate antiviral state in
murine macrophage and primary MEFs which was correlated with IFN-b production. Moreover, FimH induced the innate
antiviral responses in cells from wild type, but not from MyD88
2/2, Trif
2/2, IFN2a/bR
2/2 or IRF3
2/2 mice. Vaginal delivery
of FimH, but not LPS, completely protected wild type, but not MyD88
2/2, IFN-a/bR
2/2, IRF3
2/2 or TLR4
2/2 mice from
subsequent genital HSV-2 challenge. The FimH-induced innate antiviral immunity correlated with the production of IFN-b,
but not IFN-a or IFN-c. To examine whether FimH plays a role in innate immune induction in the context of a natural
infection, the innate immune responses to wild type uropathogenic E. coli (UPEC) and a FimH null mutant were examined in
the urinary tract of C57Bl/6 (B6) mice and TLR4-deficient mice. While UPEC expressing FimH induced a robust
polymorphonuclear response in B6, but not TLR4
2/2 mice, mutant bacteria lacking FimH did not. In addition, the presence
of TLR4 was essential for innate control of and protection against UPEC. Our results demonstrate that FimH is a potent
inducer of innate antimicrobial responses and signals differently, from that of LPS, via TLR4 at mucosal surfaces. Our studies
suggest that FimH can potentially be used as an innate microbicide against mucosal pathogens.
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Introduction
The innate immune system plays a crucial role in the early
defence against microbial infections [1,2,3,4,5,6]. A key aspect of
the innate immune response is the synthesis and secretion of type I
interferons (IFN) such as IFN-a and IFN-b. The innate immune
system detects infections through germ-line encoded pattern
recognition receptors [7], such as Toll-like receptors (TLRs).
TLRs recognize conserved structures present in large groups of
microorganisms, but not found in the host, called pathogen-
associated molecular patterns (PAMPs) [8,9,10,11,12]. Thus far,
10 TLRs have been identified in mice and humans [13,14,15,16],
with each receptor recognizing a unique set of PAMPs [17,18].
Examples of PAMPs include lipopolysaccharide (LPS, a ligand for
TLR4), flagellin (a ligand for TLR5), double-stranded RNA
(dsRNA, a ligand for TLR3), bacterial CpG DNA (a ligand for
TLR9) and profillin (a ligand for TLR11). Upon ligand binding,
TLRs initiate intracellular signalling through their cytoplasmic
Toll/IL-1 (TIR) domain. These signalling pathways can be
divided into common (MyD88-dependent) and specific (MyD88-
independent) categories. TLR2, 5, 7–9 and 11 signalling is mainly
MyD88-dependent, while TLR3 and 4 signalling is mediated
through either MyD88 or Trif.
Recently, we and others have reported that CpG ODN/TLR9
signalling leads to the induction of potent innate protection against
herpes simplex virus (HSV-2) infection both in vivo and in vitro
[3,19,20,21,22,23]. Local intravaginal (IVAG) delivery of CpG
ODN or Poly I:C resulted in rapid proliferation and thickening of
the vaginal epithelium and induction of a innate antiviral state that
did not block virus entry but inhibited viral replication in vaginal
epithelial cells. This TLR ligand-induced innate protection
correlated with production of IFN-b, but not IFN-a, IFN-c or
TNF-a. Treatment of mice lacking the IFN-a/bR with CpG or
Poly I:C did not provide innate antiviral protection against genital
HSV-2 challenge compared to control mice. More recently, it has
been shown that DC-derived IFNs are crucial for the innate
antiviral activity of CpG in the genital tract [24].
Several PAMPs of bacterial origin including LPS, flagellin,
peptidoglycan and bacterial DNA can activate the innate immune
system via TLRs [18]. FimH, the adhesion portion of type 1
fimbriae produced by most Enterobacteriaceae including uropatho-
genic E. coli, is a conserved protein involved in bacterial
PLoS Pathogens | www.plospathogens.org 1 December 2008 | Volume 4 | Issue 12 | e1000233attachment to mucosal epithelial cells [25,26,27]. Type I fimbriae
have long been implicated in bacterial urinary tract infections in
humans [25,28,29,30,31,32,33] and have been the focus of many
attempts to generate a vaccine against pathogenic Gram-negative
bacteria [26,29,34,35,36]. We have recently shown that recombi-
nant FimH protein can activate the innate immune system
through MyD88 and TLR4 in primary murine cells ([37] and un-
published data). Little is known about the antiviral or antibacterial
activity of FimH. Here we report that FimH is a potent inducer of
innate antimicrobial responses. Our in vitro and in vivo experiments
clearly show that FimH-induced innate antiviral immunity is
associated with IFN-b production and requires MyD88, Trif,
TLR4, IRF-3 and type I IFN signalling.
Results
FimH induces potent innate antiviral immunity against
HSV-2 infection in RAW264.7 cells
We have previously reported that bacterial LPS and CpG DNA
as well as Poly I:C can induce innate antiviral responses in
RAW264.7 cells. More recently, we have shown that FimH can
stimulate these cells and induce the production of TNF-a ([37] and
un-published data). Here we first examined if FimH-mediated
signalling resulted in antiviral activity. RAW264.7 cells treated
with FimH had significantly lower HSV-2 titers compared to cells
treated with PBS (Fig. 1A&B). This innate protection correlated
with the production of IFN-b, but not IFN-a or IFN-c (Fig. 1C).
Author Summary
The innate immune system is an evolutionarily conserved
defence mechanism that protects the host from infection
by microbes such as viruses, bacteria and fungi. Incoming
pathogens are recognized by a set of evolutionary
conserved receptors, including the Toll-like receptors
(TLRs), that can be found on the surface of epithelial cells
at the mucosal surface. We recently found that FimH, a
specific adhesin located at the tip of type 1 fimbriae in
uropathogenic E. coli, binds directly to TLR4. Here, we
demonstrate the biological significance of this interaction.
In the context of a natural infection, recognition of FimH
by TLR4 is important for the host to mount an innate
immune response against uropathogenic E. coli. Further-
more, we show that purified FimH protein induces a
potent innate antiviral response, both in tissue culture and
in animal models. This response is mediated predominant-
ly by the production of type I interferon. Our results
suggest that FimH is an excellent candidate for develop-
ment as a microbicide against pathogen infection.
Figure 1. Treatment of RAW264.7 cells with FimH induces the production of IFN-b and significantly reduces HSV-2 replication.
RAW264.7 cells were treated with either recombinant FimH (10 mg/mL), Poly I:C (10 mg/mL) or left untreated. Twenty-four hours post treatment cells
were infected with HSV-2 with MOI of 0.1. Twenty hours post infection cells and the supernatant were collected and after 3 freeze/thaw cycles titered
on Vero cells (A). Both FimH and Poly I:C treated cells had HSV-2 titers that were at least 2-3 logs lower compared to un-treated cells (A and B).
Supernatants of treated cells were tested for IFN-a, IFN-b and IFN-c (C). When FimH was incubated with alpha-D-Mannose (a standard blocker of
binding to mannose) and then added to RAW264.7 cells, there was no inhibition of FimH innate antiviral activity (D).
doi:10.1371/journal.ppat.1000233.g001
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[38,39,40,41]. We then examined if the mannose binding domain
of FimH is involved in the signaling. Incubation of FimH with D-
mannose had no effect on FimH-induced innate antiviral response
(Fig. 1D).
FimH induces strong innate antiviral responses (type I
IFNs) in MEFs from B6, but not from MyD88
2/2, Trif
2/2,
IFN-a/bR
2/2 or IRF-3
2/2 mice
Recently we have shown that FimH signalling required TLR4
and MyD88 pathway in murine macrophages [37]. It is well
documented that Poly I:C induces strong antiviral responses in
mouse embryonic fibroblasts (MEFs) as measured by a standard
VSV plaque reduction assay. We first examined whether FimH
could induce the production of type 1 IFNs, resulting in an innate
antiviral state in B6 MEFs. Interestingly, FimH induced similar
levels of IFN-b, but not IFN-a, in B6 MEFs compared to those
treated with Poly I:C (Fig. 2A) and provided complete protection
against VSV challenge (Fig. 2B& 3). B6 MEFs treated with FimH
also showed little or no VSV-GFP replication, as detected by GFP
fluorescence, when compared to untreated MEFs (Fig. 3A). We
then examined whether FimH-induced innate antiviral responses
were MyD88, Trif and/or type I IFN dependent. FimH failed to
provide protection against VSV challenge in MEFs deficient in
either the MyD88 or Trif adaptors, whereas Poly I:C provided
complete protection in MEFs lacking MyD88 and partial
protection in MEFs lacking Trif (Fig. 2B, 3B,C). To further
investigate whether type 1 IFNs, particularly IFN-b, were involved
in FimH-induced innate antiviral immunity, MEFs from IFN-a/
bR
2/2 or IRF-3
2/2 mice were treated with FimH or Poly I:C
and then challenged with VSV. FimH failed to induce an innate
antiviral state in the absence of either IRF-3 or type 1 IFN
signalling (Fig. 2B, 3D,E). Poly I:C induced only moderate
protection at 30 nM or 15 nM, but no significant differences in
VSV-GFP fluorescence was observed in MEFs at lower concen-
trations compared to untreated MEFs (Fig. 2A,B, 3D,E).
Vaginal delivery of recombinant FimH, but not LPS,
protects normal B6 mice from subsequent IVAG HSV-2
challenge
We have reported that the mucosal delivery of some TLR
ligands/agonists can induce an innate antiviral state and provide
complete protection against subsequent IVAG HSV-2 challenge
[3,19,22]. To examine if local delivery of FimH can provide innate
protection against subsequent IVAG HSV-2 challenge, FimH was
administered intravaginally to mice and then mice were
Figure 2. FimH induces strong innate antiviral responses in B6, but not MyD88
2/2, Trif
2/2, IRF-3
2/2 or IFN-Ra/b
2/2MEFs. B6 MEFs
were split at passage 3 and then treated with either FimH (10 mg/ml), Poly I:C (10 mg/ml) or left untreated for 24 hours. The supernatants were
removed and were used to measure levels of IFN-a and IFN-b. Both FimH and Poly I:C treatment induced significant levels of IFN-b, but not IFN-a,i n
B6 MEFs (A). In a next series of experiments B6, IRF-3
2/2, MyD88
2/2, Trif
2/2 or IFNa/bR
2/2 MEFs, at passage three, were seeded into 12-well plates,
24 hours prior to treatment. Serial dilutions of Poly I:C or FimH were made in complete 10% alpha-MEM media, then 500 ml were added directly to
the MEFs and cells were allowed to incubate at 37uC for 24 hours. Twenty-four hours post treatment the supernatants were aspirated and stored at
220uC for future use. Then 200 ml of VSV-GFP (3.18610
4 pfu/ml) in 0% alpha-MEM were added to each well and then cells were incubated for 1 hour
at 37uC with rocking every 10 minutes. After 1 hour, VSV-GFP inoculums were aspirated from each well and cells were overlayed with 1 ml of 10%
alpha-MEM /1% methylcellulose and incubated for 24 hours at 37uC. After 24 hours, VSV-GFP plaques were visualized using a Typhoon
phosphoimager. (B) Represents photomicrographs of GFP expression in MEFs treated with FimH, Poly I;C or un-treated controls. In B6 MEFs FimH as
well as Poly I:C treatment provide complete protection against VSV compared to controls. FimH failed to provide protection in MyD88
2/2, Trif
2/2 ,
IFNa/bR
2/2 or IRF-3
2/2 MEFs.
doi:10.1371/journal.ppat.1000233.g002
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treatment. FimH provided 100% protection against IVAG HSV-2
challenge compared to control mice (Fig. 4A). Moreover, HSV-2
virus particles were not present in the vaginal washes from FimH-
treated mice compared to control mice (Fig. 4B).
To further verify that the innate antiviral protection in FimH-
treated mice was due to the direct effects of FimH protein, but not
LPS or other bacterial contaminants, we performed three
experiments: 1) mice were treated with 5000 ng of LPS and then
challenged with HSV-2; 2) mice were treated with protease-
digested FimH (complete digestion was confirmed by gel
electrophoresis) and then challenged with HSV-2; 3) mice were
treated with either FimH or another component of bacterial pilin
(PapG), which were expressed, purified and prepared in the same
manner. As shown in Figure 5A neither LPS nor digested FimH
protected mice against subsequent challenge with IVAG HSV-2.
Mice treated with PapG were also not protected against IVAG
HSV-2 challenge (Fig. 5B). However, both FimH and PapG were
prepared identically and the preparations had similar levels of
LPS. Interestingly, FimH, but not LPS, induced dramatic
morphological changes in the genital mucosa, including thickening
of the vaginal epithelium and recruitment of polymorphonuclear
cells (PMNs) (Fig. 5C).
MyD88 and IFN-b signalling as well as TLR4 are required
for FimH-induced innate protection against genital HSV-
2 infection
Our in vitro observations show that FimH signalling requires
TLR4, MyD88 and type 1 IFN signalling to induce innate
antiviral activity. Thus, we examined whether vaginal delivery of
FimH could protect mice lacking these innate factors against
genital HSV-2 infection. While FimH provided nearly complete
protection in B6 mice, there was no protection against IVAG
HSV-2 challenge in FimH-treated MyD88
2/2 mice (Fig. 6A). We
also examined if type I IFNs, particularly IFN-b, were involved in
the FimH-induced innate antiviral immunity in vivo. Vaginal
delivery of FimH and Poly I:C to IFN-a/bR
2/2 and IRF-3
2/2
mice failed to protect them against IVAG HSV-2 challenge
compared to control mice (Fig. 6A). This innate protection
strongly correlated with the production of IFN-b, but not IFN-a,
levels in the vaginal washes (Fig. 6B). To ensure that the ELISA
kit could detect naturally produced IFN-a, we used supernatants
from BM-DCs treated with Poly I:C or CpG ODN and were able
to detect high levels of mIFN-a (Figure S1). Finally, to confirm that
FimH signals via TLR4, B6 and TLR4
2/2 mice were treated with
FimH and then challenged with IVAG HSV-2. FimH failed to
protect TLR4
2/2 mice but completely protected B6 mice against
genital HSV-2 challenge (Fig. 6C).
TLR4 is essential for innate response to FimH-expressing
bacteria
FimH plays an important role in the pathogenicity of
uropathogenic E. coli (UPEC) [26]. To examine whether FimH
plays a role in innate immune induction in the context of a natural
infection, we measured PMN leukocyte recruitment to the urinary
tract in B6 mice and TLR4-deficient mice following infection with
wild type UPEC and a fimH null mutant. In B6 mice, UPEC
expressing FimH induced a rapid PMN response whereas mutant
bacteria lacking FimH did not (Fig. 7A). This FimH-induced
PMN influx required TLR4, since the cellular influx was blocked
Figure 3. FimH induces strong innate antiviral responses in B6, but not MyD88
2/2, Trif
2/2, IRF-3
2/2 or IFN-Ra/b
2/2MEFs. Figure 3
shows mean GFP florescent intensity of MEFs treated with different concentrations of FimH or Poly I:C relative to untreated VSV-GFP infected cells
(RFU). Values from control un-infected wells were used as background. Values from infected, untreated, wells (positive controls) were set at 100%. B6
MEFs treated with FimH or Poly I:C had significantly lower infections (A). MyD88
2/2, Trif
2/2, IFNa/bR
2/2 and IRF-3
2/2 MEFs treated with FimH
showed no significant reduction in relative GFP fluorescence compared to untreated positive controls (B–E). Poly I:C treatment provided complete
protection against VSV in My D88
2/2, but not Trif
2/2, IFNa/bR
2/2 or IRF-3
2/2 MEFs.
doi:10.1371/journal.ppat.1000233.g003
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enumerated in the bladder 24 h after infection. TLR4 was
required for control of infection in the bladder, as TLR4
2/2 mice
had ,1.5-log more wild type bacteria in the bladder at 24 h
compared to B6 mice (Fig. 7C), which correlated with a loss of
PMN recruitment in the TLR4
2/2 mice. Deletion of fimH
resulted in decreased colonization of the bladder but this decrease
was not overcome in a TLR4
2/2 background, confirming that
while FimH is important for UPEC colonization of the bladder
[33], FimH-independent signaling through TLR4 is not likely a
major contributor to infection control in B6 mice.
Discussion
We have demonstrated here that FimH can induce a potent
innate antiviral state, both in vitro and in vivo. Pre-treatment of
MEFs from B6 mice, but not MyD88
2/2, Trif
2/2, IRF-3
2/2 or
IFN-a/bR
2/2 mice, with FimH conferred protective antiviral
responses. Mucosal delivery of FimH, but not LPS, provided
complete protection against IVAG HSV-2 challenge in B6 mice
while it failed to provide any protection in MyD88
2/2 mice.
Moreover, the FimH-induced innate antiviral immunity was
associated with the induction of IFN-b in the genital tract and
required TLR4 and IRF-3. To evaluate the biological significance
of FimH in host pathogen interaction, we have examined the host
innate response in FimH knockout uropathogenic E.coli in the
presence and absence of TLR4. TLR4 was required for the
induction of innate immune responses against UPEC.
We have shown that FimH requires TLR4 and MyD88 to
activate murine primary macrophages. In addition we have also
reported that dsRNA and CpG ODN confer protection against
HSV-2, both in vitro and in vivo [3,19,22]. Similar to Poly I:C and
CpG, the FimH-induced innate antiviral state correlates with IFN-
b, but not IFN-a or IFN-c production. Although we have observed
high levels of TNF-a, it is unlikely that the FimH induced innate
antiviral activity is mediated via TNF-a. Previous work showed
Figure 4. Local delivery of FimH induces potent innate antiviral immunity against IVAG HSV-2 challenge. Six- to eight-week-old B6
mice were treated with Depo-Provera to synchronize their susceptibility. Four days later, mice were treated locally with FimH or Poly I:C. Twenty-four
hours post treatment mice were challenged IVAG with a lethal dose of HSV-2 (10
4 pfu). Challenged mice were monitored daily for genital pathology,
survival and vaginal virus titers. Mice that received FimH or Poly I:C were protected against IVAG HSV-2 challenge (A) and showed no HSV-2 titers in
the genital washes compared to naı ¨ve mice (B).
doi:10.1371/journal.ppat.1000233.g004
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them against HSV-2 infection [42]. FimH also induces significant
levels of NO production. Both IFN-b and NO are able to block
HSV-2 replication [1,2,43,44,45].
We have observed induction of a strong innate antiviral state by
FimH that correlated with the production of IFN-b, and required
TLR4. It was first important to establish whether, in addition to
TLR4, FimH binding to its natural receptor, mannose, is essential
for induction of innate antiviral activity. It is well documented that
FimH adhesin of uropathogenic E. coli type 1 fimbriae bind to
mannose on epithelial cells. Blocking the mannose-binding portion
of FimH with D-mannose had no effect on the FimH-induced
innate antiviral activity. This suggested that FimH may bind to
TLR4 independent of mannose to induce antiviral responses. We
were unable to detect any IFN-a from FimH treated RAW264.7
or B6 MEFS by ELISA. This suggested that IFN-b is the key
factor in the FimH-induced innate antiviral state. Given the
importance of the transcription factor IRF3 in the production of
IFN-b in fibroblast and epithelial cells, FimH also failed to induce
IFN-b production from IRF-3
2/2 MEFs and did not protect these
cells against VSV. Taken together, these data indicate that FimH
signals through IRF3 in the induction of an innate antiviral
response.
We and others have shown that mucosal delivery of TLR
ligands protect mice against subsequent IVAG HSV-2 challenge
[3,19,20,21,22,46]. More recently, we have found that the TLR
ligand-induced innate antiviral responses against IVAG HSV-2
strongly correlate with the production of IFN-b, but not IFN-a
[47]. Our data show that FimH activity of FimH against genital
HSV-2 challenge requires MyD88
2/2, IRF-3
2/2 IFN-a/bR
2/2
and TLR4
2/2 mice did not provide any protection against
subsequent IVAG HSV-2 challenge compared to B6 control. FimH
also induced significantly lower levels of IFN-b in MyD88
2/2 mice
while IFN-b was not detectable in IRF-3
2/2 mice compared to B6
control mice. This clearly suggested that FimH-induced innate
antiviral activity against IVAG HSV-2 is mediated via TLR4,
MyD88 and type 1 IFNs, particularly IFN-b.
Since we purified recombinant FimH from bacteria, it was
essential to confirm that the antiviral activity seen with the purified
FimH was not due to LPS contamination and/or other possible
minor proteins. Our in vitro and in vivo data clearly showed that the
antiviral activity of FimH was not due to contamination with LPS.
We have used all possible controls to confirm that FimH was
responsible for the innate antiviral responses. First, control samples
from bacteria that contained empty vector and processed in
exactly the same manner as FimH had no antiviral activity
assuring that the antiviral response seen with FimH is not due to
low levels of LPS contamination. Second, both enzymatic
digestion and heat inactivation of FimH protein significantly
abrogated the activity of FimH protein in vitro and in vivo. To also
Figure 5. Induction of innate antiviral immunity by FimH at the genital mucosa is independent of LPS or other bacterial
contaminants. Six- to eight-week-old B6 (N=5 per group) mice were treated with Depo-Provera to synchronize their susceptibility to IVAG HSV-2
challenge. Four days later, mice were treated locally with intact FimH, digested and/or head-inactivated FimH or LPS. Another group of mice were
treated with FimH, PapG or left untreated. Twenty-four hours post treatment mice were challenged IVAG with a lethal dose of HSV-2 (10
4 pfu).
Challenged mice were monitored daily for genital pathology, survival and vaginal virus titer. (A) Mice that received FimH (N) were protected against
IVAG HSV-2 challenge compared to digested FimH (m), LPS (&) or naı ¨ve (%) mice. Treatment of mice with PaPG did not provide any protection
against IVAG HSV-2 challenge (B). Figure 5C shows photomicrograph of vaginal tissue cut in cross section and stained with H&E.
doi:10.1371/journal.ppat.1000233.g005
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antiviral responses, we performed several experiments. First; local
delivery of LPS or digested/heat-inactivated FimH protein gave
no protection against subsequent IVAG HSV-2 challenge in B6
mice compared to treatment with intact FimH protein. Second;
local delivery of recombinant PapG protein, another adhesin of
fimbriated bacteria which was prepared exactly with the same
protocol as FimH, gave no protection against subsequent IVAG
HSV-2 challenge in B6 mice compared to FimH. However, PapG
protein had the same levels of LPS compared to FimH. In
addition, our in vitro experiments clearly showed that low levels of
LPS present in our samples cannot provide any protection against
viral infections. In addition we have shown that FimH can directly
bind TLR4 ([37] and un-published data). Furthermore, while
FimH induced dramatic changes in genital mucosa, there was no
difference in the histomorphology of the genital mucosa from LPS-
or PBS-treated mice. More importantly, our recent data indicates
that FimH signals in cells unresponsive to LPS ([37] and un-
published data).
It is well known that FimH play an import role in attachment of
bacteria to epithelial cells and contributes to pathogenecity of
UPEC. Our data show that TLR4 is involved in FimH signalling
with epithelial cells. FimH-expressing UPEC were able to induce
recruitment of PMNs to the urinary tract of wild type mice, while
isogenic bacteria lacking FimH did not. Interestingly, this response
is controlled by TLR4 expression and is abolished when we used
FimH
2 UPEC, even in the presence of TLR4. These data are
similar to the PMN response seen following infection with a type I
fimbriated derivative of non-adhesive E. coli [48]. Because these
UPEC strains share expression of another TLR4-activating PAMP
(LPS), these data suggest that the dominant innate immune-
activating PAMP on uropathogengic E. coli may in fact be FimH.
In support of this, deletion of fimH resulted in decreased
colonization of the bladder as reported previously [33] but the
level of colonization by fimH
2 UPEC was similar in a B6 and
TLR4
2/2 background. These data suggest that FimH-indepen-
dent signaling through TLR4 is not likely a major contributor to
infection control in B6 mice.
This is the first report to show that FimH has potent innate
antiviral activity which also requires TLR4, MyD88, Trif, IRF-3
and type 1 IFNs, particularly IFN-b. So far, TLR ligands such as
dsRNA, ssRNA, and CpG DNA have been associated with the
induction of innate antiviral immunity. Protein ligands of TLRs
have not been associated with the induction of innate antiviral
immunity. Here, however, we demonstrate that FimH, but not
LPS, mediates innate antiviral activity at the genital mucosa. It is
of particular interest that both TLR5 and TLR11 ligands signal
via MyD88, whereas FimH protein signals through both MyD88
and Trif, leading to activation of the IRF-3 pathway. Results from
this study may provide the basis for a novel mucosal innate
microbicide for a vast variety of mucosal viral infections such as
HSV-2, HIV-1 or other sexually transmitted infections.
Materials and Methods
Mice
Female C57BL/6, 129SVPasCrl mice, 8–12 weeks old, were
purchased from Charles River Laboratory (Quebec, Canada).
TLR4
2/2 mice were purchased from Jackson laboratory (Bar
Harbor, USA). Breeding pairs of IFNa/bR
2/2 were kindly
provided by Rolf M. Zinkernagel (Zu ¨rich, Switzerland). Breeding
pairs of IRF-3
2/2, MyD88
2/2 and Trif
2/2 mice were kindly
provided by Dr. T. Taniguchi (via Dr. T. Moran), Dr. S. Akira (via
Dr. D. Golenbock) and Dr. B. Beutler, respectively. All mice were
housed in level B rooms which followed a 12 hour day and 12 hour
night schedule, and were maintained under standard temperature
controlled conditions.
Cells, viruses and reagents
RAW264.7, HEL fibroblasts and BJ fibroblasts cells were
purchased from ATCC. B6, IRF-3
2/2, MyD88
2/2, Trif
2/2 and
IFNa/bR
2/2 murine embryonic fibroblasts (MEFs) were pre-
pared from gestation day 13.5 in a-MEM with 20% FBS and
weaned then grown in 10% a-MEM for experiments. 293, 293-
hTLR4 and 293-hTLR4-CD14/MD2 cells were purchased from
InvivoGen and maintained in 10% DMEM supplemented with
10ug/mL blasticidin (293-hTLR4) or 10ug/mL blasticidin and
50ug/mL HygroGold (293-hTLR4-CD14/MD2). HSV-2 strain
333 was grown and titred as previously described [49]. VSV
expressing GFP was kindly provided by Dr. Brian Lichty
(McMaster University, Hamilton, ON). GM-CSF was purchased
from R&D. a-D-manosidase, LPS (L26-54) and Poly I:C were
purchased from Sigma (Oakville, ON, Canada). Depo-Provera
was purchased from Upjohn (Don Mills, ON, Canada).
Purification of FimH
The fimH gene from avian pathogenic E. coli strain EC99 (O78)
was cloned into pQE-30 and expressed in BL-21 competent E. coli.
FimH expression and purification were performed as previously
described [50]. Briefly, Protein expression was induced by adding
1M IPTG to a final concentration of 1 mM and induction
continued for a period of 5 hours. Bacterial pellets were lysed and
protein isolation continued under denaturing conditions utilizing
Ni-NTA affinity chromatography. Isolated protein fractions were
then dialyzed in a 10-kDa Slidlyzer dialysis cassette against PBS.
The LPS contraction in the purified FimH protein was determined
using Limulus Amebocyte Lysate LPS detection kit according to
the manufacturer’s protocol.
Treatment of RAW264.7 cells and MEFs with ligands
RAW264.7 cells were treated with FimH (10 mg/ml), Poly I:C
(10 mg/ml) or left un-treated. Twenty-four hours post treatment
the supernatants were collected and stored at -20uC for further
study. The cells were then infected with HSV-2, MOI of 0.1.
Twenty to twenty-two hours post infection the cells and
Figure 6. TLR4 and Type 1 IFN signalling, particularly IFN-b, are required for FimH-induced innate protection against HSV-2
challenge. Six- to eight-week-old female B6, IRF-3
2/2, MyD88
2/2 or IFNa/bR
2/2 were treated with Depo-Provera. Four days later, mice were treated
with either FimH (40 mg/mouse) or left untreated. Twenty-four hours post treatment mice were challenged with a lethal dose IVAG of HSV-2 (10
4 pfu).
Challenged mice were monitored daily for genital pathology, survival and vaginal virus titers. (A) Only B6 mice that received FimH (N) showed 90%
protection against IVAG HSV-2 challenge compared to naive B6 (#) or FimH treated MyD88
2/2 (m), IFNa/bR
2/2 (&) or IRF-3
2/2 (¤) mice. Figure
11b shows that local delivery of FimH induces production of significant levels IFN-b in B6, but not MyD88
2/2 mice. Six- to eight-week-old female B6
or MyD88
2/2 mice were treated with either FimH (40 mg/mouse) or left untreated. (B) Vaginal washes were collected at 12 and 24 hours post
treatment and were used to measure levels of IFN-b and IFN-a using ELISA. Treatment of MyD88
2/2 mice induced significantly (p,0.001) lower levels
of IFN-b compared to B6 controls. (C) 6–8 week-old B6 mice TLR4
2/2 mice were treated with FimH and then challenged with IVAG HSV-2 as described
above. Local delivery of FimH failed to provide innate protection against IVAG HSV-2 challenge in TLR4
2/2 mice.
doi:10.1371/journal.ppat.1000233.g006
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Passage 3 MEFs from B6, IRF-3
2/2, MyD88
2/2, Trif
2/2 and
IFNa/bR
2/2 mice were split into 12-well plates and then treated
with various concentrations of FimH, Poly I:C or LPS or left un-
treated. Twenty-four hours post treatment, MEFs were infected
with VSV-GFP. Levels of GFP fluorescence were visualized and
quantified using a Typhoon
TM scanner (GE Healthcare) 24 hours
post-infection.
Local delivery of TLR ligands, genital HSV-2 inoculation
and vaginal virus titration
B6, TLR4
2/2,IRF-3
2/2, MyD88
2/2 and IFNa/bR
2/2 mice,
6–8 weeks old, were subcutaneously (sc) injected with 2 mg of
progesterone/mouse (Depo-Provera). Four days later the mice
were anaesthetized and treated vaginally with FimH (40 mg/
mouse) or Poly I:C (100 mg/mouse). Twenty-four hours after
treatment the mice were anesthetised, placed on their backs, and
infected IVAG with a lethal dose of HSV-2 in 10 ml of PBS for at
least 45 min while being maintained under anaesthesia. Vaginal
washes were collected daily after infection (days 1–3) by pipetting
2630 mL of PBS into and out of the vagina 6–8 times. Viral titers
in IVAG washes were determined by plaque assay on monolayers
of Vero cells as previously described [49]. Treated mice were also
monitored daily for genital pathology and survival for up to 4
weeks. Pathology was scored on a five point scale. Zero indicated
no infection; 1, slight redness of external vagina; 2, swelling and
redness of external vagina; 3, severe swelling of external vagina
and hair loss in the surrounding area; 4, ulceration of vaginal
tissue, redness and swelling; 5, continued ulceration, redness,
swelling and sometimes paralysis in back legs, at which point the
mice were euthanized.
Histomorphology of the genital tract
To study the effects of FimH or LPS on vaginal tissue
morphology, progesterone-treated mice received FimH (40 mg/
mouse) or LPS (5 mg/mouse). After 24 h, vaginal tissue was
removed, fixed in 4% paraformaldehyde, embedded in paraffin,
and sectioned at 5 mm for hematoxylin and eosin staining.
ELISA for IFN-a, IFN-b, TNF-a, IFN-c and IL-8
IFN-a, IFN-b, IFN-c and IL-8 ELISAs were conducted using
Quantikine Murine Kits from R&D Systems (Minneapolis, MN,
USA) according to the manufacturer’s instructions. IFN-a and
IFN-b ELISAs were conducted using PBL Biomedical kits from
PBL (Piscataway, NJ, USA). The IFN-a ELISA kit detects mouse
IFN-aA, IFN-a1, IFN-a4, IFN-a5, IFN-a6, and IFN-a9, with a
detection limit of 10 pg/ml.
Bacteria and experimental urinary tract infection
A human cystitis isolate of uropathogenic Escherichia coli was used
for experimental urinary tract infection of mice. E. coli NU14-1,
which does not express FimH due to a disruption of the fimH gene,
and E. coli NU14, which is the isogenic wild type parent strain, were
kindly provided by Dr. Scott Hultgren (Washington University, St.
Louis, MO). E. coli were cultured in LB broth with streptomycin at
50 mg ml. For mouse infection studies, bacteria were grown
overnight in LB broth, washed in 0.85% saline, and resuspended
in saline to a concentration of ,10
9 colony forming units (cfu) per
ml. B6 mice and TLR4
2/2 were infected with 0.1 ml (10
8 cfu) of
bacterial suspension. A soft catheter (0.7 mm) placed in the urethra
of anaesthetized mice and the bacterial were delivered into balder.
Urine was collected 0, 2, 6 and 24 hours post-infection and
polymorphonuclear leukocytes were quantified using a haemocy-
tometer. Twenty-four hours after infection, the bladders were
removed, homogenized and the bacterial load was enumerated.
Statistical analysis
Statistical differences among the viral titers were determined by
analysis of variance followed by Tukey’s test. The statistical
Figure 7. TLR4 is required for innate response to FimH+ UPEC.
(A) Polymorphonuclear response to FimH+ and FimH- UPEC. B6 and
TLR4
2/2 female mice, aged 8–10 weeks, were used for the experiments.
For infections, 0.1 ml (10
8 cfu) of FimH+ or FimH2 UPEC was injected
into the bladder of anesthetized mice using a soft catheter (0.7 mm)
placed in the urethra. Urine was collected from uninfected and infected
mice and the cfu was enumerated. (N=5 per time point). Polymor-
phonuclear leukocytes in urine were quantified using a haemocytom-
eter. (B) UPEC colonization of the bladder. B6 and TLR4
2/2 mice were
infected with either wild type or fimH
2 UPEC as described in Materials
and Methods. Twenty-four hours after infection, the bladders were
removed, homogenized and the bacterial load was enumerated (C).
Each data point represents one infected animal and data shown is from
three independent experiments. Horizontal lines within each scatter of
data represent the geometric mean. B6 vs TLR
2/2 infected with wild
type UPEC (P,0.001, ANOVA); ns, not significant.
doi:10.1371/journal.ppat.1000233.g007
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expressing cells were determined by the x
2 test. A P value of ,0.05
was considered statistically significant. An unpaired t test was used
to determine significant differences in cytokine production.
Supporting Information
Figure S1 Supplementary Data
Found at: doi:10.1371/journal.ppat.1000233.s001 (4.22 MB TIF)
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